Atherosclerosis Drugs Global Market Report 2023 – By Drug Class (Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes), By Route Of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2023-2032

Cardiac biomarkers testing refers to the tests to evaluate the quantities of cardiac biomarkers in blood. It is used to diagnose, assess, and keep track of people who may have acute coronary syndrome (ACS). The types of biomarkers in cardiac biomarkers testing are creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA) and others. Creatine kinase (CK-MB) refers to a blood test that looks for a particular enzyme. The various applications involved are congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis and others, with hospitals and specialty clinic end-users. The global cardiac biomarkers testing market is segmented - 1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified albumin (IMA), Other Biomarkers Types 2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications 3) By End-User: Hospitals, Specialty Clinics The global cardiac biomarkers testing market size is expected to grow from $10.83 billion in 2022 to $12.10 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac biomarkers testing market size is expected to grow to $18.46 billion in 2027 at a CAGR of 11.1%. The increasing prevalence of cardiovascular diseases is expected to boost the growth of the cardiac biomarkers testing market going forward. Cardiovascular disease refers to a type of condition that affects the heart or blood vessels. Cardiac biomarker tests assist in determining the levels of biomarkers to immediately determine the severity of a heart attack and its magnitude. Hence, an increase in the prevalence of cardiovascular diseases will lead to an increase in the demand for cardiac biomarker testing solutions. For instance, according to a report published by the American Heart Association, a US-based voluntary organization dedicated to fighting heart disease and stroke, in 2020, cardiovascular disease (CVD) was responsible for about 19.1 million deaths globally. The age-adjusted mortality rate was 239.8 per 100,000 people. The age-adjusted prevalence rate was 7354.1 per 100,000. Eastern Europe and Central Asia had the highest rates of CVD-related mortality in 2020. Therefore, an increase in the prevalence of cardiovascular diseases is driving the growth of the cardiac biomarkers testing market. Major players in the cardiac biomarkers testing market are Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company (BD), Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics, Merck KGaA, Beckman Coulter Inc., and QIAGEN N.V. Product innovations are a key trend gaining popularity in the cardiac biomarker testing market. Major companies operating in the cardiac biomarker testing market are focusing on developing innovative products to sustain their market position. For instance, in October 2021, Siemens Healthcare GmbH, a Germany-based medical technology company, launched the Atellica VTLi Patient-Side Immunoassay Analyzer. The unique feature of the Atellica VTLi Patient-Side Immunoassay Analyzer is its high-sensitivity troponin I test from a fingerstick sample. Clinicians and healthcare professionals can enhance outcomes for patients by using it to help diagnose a heart attack fast and reliably in eight minutes. In September 2021, Shenzhen Mindray Bio-Medical Electronics Co. Ltd, a China-based medical instrumentation manufacturer, acquired HyTest Invest Oy and its subsidiaries (“HyTest”) for an undisclosed amount. with this acquisition, Mindray will have excellent R&D and innovation capabilities for raw materials and will help HyTest maintain its status as a world leader in the upstream IVD raw material industry by supporting its continued investment in R&D as well as strengthening and improving its core competitive edge. HyTest Ltd is a US-based provider of antibodies and antigens focused on the IVD market including cardiac indicators, inflammation, tumor markers and others. North America was the largest region in the cardiac biomarkers testing market in 2022. The regions covered in the global cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiac biomarkers testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cardiac biomarkers testing market includes revenues earned by entities by providing ischemia-modified albumin (IMA), peptides, and C-reactive protein (CRP) biomarkers testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cardiac biomarkers testing market research report is one of a series of new reports from The Business Research Company that provides cardiac biomarkers testing market statistics, including cardiac biomarkers testing industry global market size, regional shares, competitors with cardiac biomarkers testing market share, detailed cardiac biomarkers testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac biomarkers testing industry. This cardiac biomarkers testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cardiac biomarkers are chemicals released by heart into the blood when it is injured or under stress. It used for the detection and measurement of various cardiac vascular diseases. The main types of cardiac biomarkers are creatine kinase (CK-MB), trophonins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), and others. Creatine kinase (CK) is an enzyme found in various tissues in the body, including muscle and brain tissue, used in the diagnosis of myocardial infarction (MI), commonly known as a heart attack. They are used at locations such as point-of-care testing and laboratory testing in a variety of applications, including testing for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), atherosclerosis, and others. These are used by hospitals and specialty clinics. The global cardiac biomarkers market is segmented - 1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types 2) By Location Of Testing: Point Of Care Testing, Laboratory Testing 3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications 4) By End User: Hospitals, Specialty Clinics The global cardiac biomarkers market size is expected to grow from $15.22 billion in 2022 to $17.22 billion in 2023 at a compound annual growth rate (CAGR) of 13.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac biomarkers market size is expected to reach $27.88 billion in 2027 at a CAGR of 12.8%. The rising prevalence of cardiovascular disorders is expected to propel the growth of the cardiac biomarker market going forward. Cardiovascular disorders are diseases that affect the heart and blood vessels and include conditions such as coronary artery disease, heart failure, and stroke. Cardiac biomarkers are released into the bloodstream in response to certain cardiovascular disorders, such as myocardial infarction (heart attack), heart failure, and arrhythmias, that can be measured using laboratory tests, and their levels can provide important diagnostic and prognostic information. For instance, in 2020, according to the Center for Disease Control and Prevention, the US national public health agency, about 697,000 people in the United States died from heart disease—that’s 1 in every 5 deaths. In addition, around 12.1 million people in the U.S. are expected to suffer from atrial fibrillation (A-Fib) by 2030. Therefore, the rising prevalence of cardiovascular disorders is driving the growth of the cardiac biomarker market. Major players in the cardiac biomarkers market are bioMerieux Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., and Roche Diagnostics. Technological advancements are a key trend gaining popularity in the cardiac biomarker market. Companies operating in the cardiac biomarker market are adopting new technologies to sustain their position in the market. For instance, in April 2021, Roche Diagnostics, a Switzerland-based healthcare company, introduced five new solutions for two significant cardiac biomarkers, highly sensitive cardiac troponin T (cTnT-hs) and the N-terminal pro-brain natriuretic peptide test (NT-proBNP), using Elecsys technology. These solutions support cardiac risk identification and improve diagnosis and help identify cardiovascular risk, better diagnose patients and support early treatment. In September 2021, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a China-based medical devices, and solutions provider, acquired HyTest Ltd. for an undisclosed amount. With this acquisition, Mindray aims to strengthen its position in the global IVD market and expand its presence in Europe and other international markets. Also, Mindray aims to further advance its research and development efforts and encourage the exploration of new technologies and academic collaborations. HyTest Ltd. is a Finland-based provider of in-vitro diagnostic (IVD) reagents with expertise in cardiac biomarkers. North America was the largest region in the cardiac biomarkers market in 2022. The regions covered in the global cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiac biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cardiac biomarkers market consists of sales of assays and reagents, point-of-care testing (POCT) devices, instruments, and software solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resale along the supply chain, either further along the supply chain or as part of other products. The cardiac biomarkers market research report is one of a series of new reports from The Business Research Company that provides cardiac biomarkers market statistics, including cardiac biomarkers industry global market size, regional shares, competitors with a cardiac biomarkers market share, detailed cardiac biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac biomarkers industry. This cardiac biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lipid panel testing to a blood test that measuring the levels of various lipids or fats in the blood. It is used to assess a person's risk of developing cardiovascular disease. The main lipid panel testing product and services are devices, kits, and services. Devices, such as analyzer machines, refer to the equipment used to perform lipid panel testing. The various prescription modes are prescription-based testing, and otc-based testing applied in hyperlipidemia, hypertriglyceridemia, familial hypercholesterolemia, hypo-lipoproteinamia, tangier disease, atherosclerosis, and others. The various end users are hospital, specialty clinics and physician offices, pathology laboratories, diagnostic clinics, ambulatory surgical centers, reference laboratories, academic and research institutes, and others. The global lipid panel testing market is segmented - 1) By Product And Services: Devices, Kits, Services 2) By Prescription Mode: Prescription-Based Testing, OTC-Based Testing 3) By Application: Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hypo-Lipoproteinamia, Tangier Disease, Atherosclerosis, Other Applications 4) By End User: Hospital, Specialty Clinics And Physician Offices, Pathology Laboratories, Diagnostic Clinics, Ambulatory Surgical Centers, Reference Laboratories, Academic And Research Institutes, Other End-Users The global lipid panel testing market size is expected to grow from $9.43 billion in 2022 to $10.28 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global lipid panel testing market size is expected to reach $13.93 billion in 2027 at a CAGR of 7.9%. The increasing number of cardiovascular and diabetic diseases is expected to boost the lipid panel testing market going forward. Cardiovascular disease is a group of conditions that affect the heart and blood vessels, whereas Diabetes is a metabolic disorder that affects the body's ability to produce insulin effectively, leading to high blood sugar levels. Lipid panel testing is an essential diagnostic tool for identifying individuals at high risk of developing cardiovascular diseases or already developed cardiovascular disease. It is also be used to monitor the effectiveness of treatment in individuals who have already developed cardiovascular or diabetes disease, allowing healthcare providers to adjust treatment plans as needed to achieve target lipid levels and reduce the risk of another ailment. For Instance, according to The National Heart, Lung, and Blood Institute, a US-based Institute of the National Institutes of Health, U.S. mortality from March to August 2020, 76,767 people perished from cardiovascular disease, which affects the blood arteries that support the brain and related systems, and 339,076 people perished from heart disease. Furthermore, in 2022, according to the Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, a US-based government agency, diabetes cases in US is increased to reach 37.3 million in 2022. Therefore, improving cardiovascular and diabetic diseases will drive the lipid panel testing market forward. Major players in the lipid panel testing market are Abbott, Beckman Coulter Inc., F. Hoffmann-La Roche Ltd., Randox Laboratories Ltd., Thermo Fisher Scientific Inc., PTS Diagnostics, Quest Diagnostics Incorporated., Alere Inc., EuroMedix, Boston Heart Diagnostics Corporation, Eurofins Scientific, Spark Diagnostics Pvt Ltd., Everlywell Inc., Horiba ABX SAS, and Siemens Healthcare GmbH. Product innovations are a key trend gaining popularity in the lipid panel testing market. Major companies operating in the lipid panel testing market are focused on developing innovative products to sustain their position in the market. For Instance, in October 2022, Boston Heart Diagnostics, a US-based biotechnology company released LipoMap, a panel of 33 lipid, lipoprotein, and apolipoprotein tests, with most comprehensive assessments of lipid metabolism commercially available. It uncovers treatable and reversible lipid abnormalities that cause cardiovascular disease (CVD), allowing for greater personalization of treatment and follow-up testing. In August 2020, Croda International plc, a UK-based specialty chemicals company, acquired Avanti Polar Lipids for an undisclosed amount. With this acquisition, Avanti will carry on with its current brand and management group and will join Croda's Life Sciences division for quickly expanding Health Care division. Avanti Polar Lipids Inc. is a US-based pharmaceutical company that offers a wide range of products, including phospholipids for lipid panel testing. North America was the largest region in the lipid panel testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the global lipid panel testing market during the forecast period. The regions covered in the global lipid panel testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lipid panel testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The lipid panel testing market consists of revenues earned by entities by providing high cholesterol testing and lipoprotein analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The lipid panel testing market also includes sales of cholesterol test kit, lipid profile analyzer, and cholesterol self-test kit which are used in providing testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The lipid panel testing market research report is one of a series of new reports from The Business Research Company that provides lipid panel testing market statistics, including lipid panel testing industry global market size, regional shares, competitors with a lipid panel testing market share, detailed lipid panel testing market segments, market trends and opportunities, and any further data you may need to thrive in the lipid panel testing industry. This lipid panel testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-hypertensive drugs refer to a group of medications used to treat high blood pressure (high blood pressure). The goal of antihypertensive therapy is to prevent the negative effects of high blood pressure, such as myocardial infarction and stroke. The main therapeutics of anti-hypertensive drugs are diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators. Diuretics, also known as water pills, are medications that increase the amount of water and salt excreted by the body in the form of urine. The various sources of diseases include primary hypertension and secondary hypertension, which are treated in hospitals, clinics, and at home care. The global anti-hypertensive drugs market is segmented - 1) By Therapeutics: Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators 2) By Disease Source: Primary Hypertension, Secondary Hypertension 3) By End Users: Hospitals, Clinics, Homecare The global anti-hypertensive drugs market size will grow from $37.65 billion in 2022 to $38.70 billion in 2023 at a compound annual growth rate (CAGR) of 2.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The anti-hypertensive drugs market size is expected to grow to $41.19 billion in 2027 at a CAGR of 1.6%. A sedentary lifestyle is a major driver of the growth of the anti-hypertensive drug market. Consumption of junk food, lack of proper healthy and balanced diet, and lack of proper sleep due to irregular work shifts have contributed to the increase in hypertension. Hypertension is the underlying factor for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Once the patient is diagnosed with hypertension, patients are required to use the drugs to control hypertension based on the severity of the condition. Furthermore, in June 2021, according to the World Health Organization data 2021, a Switzerland-based Government agency responsible for international public health, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This creates a sustainable demand for the product and acts as a prominent driver for the growth of the market. Major players in the anti-hypertensive drugs market are Merck & Co. Inc., Astra Zeneca PLC., Daiichi Sankyo Company Limited, Johnson & Johnson Ltd., Pfizer Inc., Novartis AG, Sanofi SA, United Therapeutics, Ranbaxy Laboratories, Bayer AG, Lupin Limited, Boehringer Engelheim GmbH, Sun Pharmaceuticals LLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Roche, Abbott, Gilead, Actelion, and Teva Pharmaceutical Industries Ltd. Low awareness of the antihypertensive drugs amongst the population is one of the major restraints in the anti-hypertensive drugs market. Firstly, most people in developing nations neglect their health checkups and are not aware of their existing hypertension condition in them until they detect extreme symptoms. Secondly, persons diagnosed with hypertension are not adherent to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thereby posing a huge challenge to the anti-hypertensive drugs market. For example, BMC Research notes published a research survey (from a developing country) which states that out of the total 112 hypertensive subjects with stroke, only 17% of them were adherent to antihypertensive medications. Lack of awareness and low drug adherence restraint the growth of the antihypertensive market. Of late, there has been a rise in the use of combination therapies compared to monotherapy treatment. Monotherapy is the treatment of hypertension with a single drug, while the use of combinations of drugs (Combination Therapy) allows for action on several different hypertensive mechanisms. When the two drugs are combined with different mechanisms of action, the effect is two to five times greater than monotherapy. Increasing the dose of monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive agents with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%. Thus, the use of combination therapy provides greater protection to a target organ than increasing the dose of monotherapy. The trend of using combination therapy is thus more effective and is being widely accepted as well. The US Food and Drug Administration (FDA) issued guidance on developing fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two-drug combinations of previously approved products. The US FDA expects to see a reduction in adverse effects for combinations that include doses below each drug’s maximum dose compared to single drug regimens at their maximum dose. Earlier physicians typically started a patient on a single drug and titrated up to a maximum dose before adding additional drugs to their program, current guidelines recommend starting patients on two drugs at less than their full doses. Hence, this guidance would keep a check on fixed-combination drugs. North America was the largest region in the anti-hypertensive drugs market in 2022. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the global anti-hypertensive drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The anti-hypertensive drugs market consists of sales of thiazide-type diuretics, beta-blocker metoprolol, olmesartan, and HCTZ. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The anti-hypertensive drugs market research report is one of a series of new reports from The Business Research Company that provides anti-hypertensive drugs market statistics, including anti-hypertensive drugs industry global market size, regional shares, competitors with an anti-hypertensive drugs market share, detailed anti-hypertensive drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-hypertensive drugs industry. This anti-hypertensive drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acne drugs refer to medications that aid in the treatment of acne scarring, blackheads, whiteheads, and other more severe types of the condition. It functions either by treating bacterial infections or by lowering edoema and oil production. Usually, it takes four to eight weeks before prescription acne medications start to work. Your acne might not go away completely for several months or even years. The main types of acne drugs are inflammatory acne drugs and non-inflammatory acne drugs. Inflammatory acne drugs refer to the drugs that are used to treat inflammatory acne problems such as mild to moderate inflammatory acne. The various therapeutic classes include retinoids, antibiotics, salicylic acid, and benzoyl peroxide that are used by various end users such as hospitals and clinics, pharmacies and drug stores, and ambulatory surgical centers. The global acne drugs market is segmented - 1) By Type: Inflammatory Acne Drugs, Non-Inflammatory Acne Drugs 2) By End User: Hospitals & Clinics, Pharmacies & Drug Stores, Ambulatory Surgical Centres 3) By Therapeutic Class: Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide The global acne drugs market size will grow from $5.44 billion in 2022 to $5.74 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global acne drugs market size is expected to grow to $6.90 billion in 2027 at a CAGR of 4.7%. An increase in the disposable income of people is one of the major drivers in the acne drug market. An increase in disposable income is usually due to an improved economy leading to increased wages and salaries and boosting healthcare expenditure. According to the Office For National Statistics (UK), in 2020, the average household disposable income in the UK was £30,800 ($37,830), an increase of 2.3% from 2019. The rise in disposable income and increased expenditure on facial care products is expected to continue, thereby driving the market in the forecast period. Major players in the acne drugs market are Allergan PLC., Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., GlaxoSmithKline PLC., Bayer AG, Stiefel Laboratories Inc., Ranbaxy Laboratories Limited, Pfizer Inc., Sun Pharmaceutical Industries Limited, Mayne Pharma Group Limited, Mylan N.V., Cipher, Daiichi Sankyo Company, Ltd., Guthy-Renker LLC., Medicis Pharmaceutical Corporation, Foamix Pharmaceuticals, BioPharmX, In, Roche Holding AG, F. Hoffmann-la Roche Ltd., Anterios Inc., AndroScience, Oculus Innovative Sciences, Aqua Pharmaceuticals, Skinvisible Pharmaceuticals and Prestium Pharma Inc. Acne drugs are a major problem worldwide, close to 90% of people suffer from some sort of acne drug. In America alone, close to 12 million people suffer from a severe acne drug problem, that can lead to scarring of the skin if left untreated, as a result, many people purchase Acne drug care drugs and products. The presence of alternatives for acne drug treatment is one of the restraints on the acne drug market. Due to the availability of multiple alternatives, patients tend to choose one amongst many options based on price, side effects, duration, and many more. This increases the competition and hence, the competition cuts down a significant portion of business for the acne drugs market. For example, some of the alternatives for acne drug treatment apart from acne drugs are Ayurveda, home remedies, laser and photodynamic therapy, and extraction of whiteheads and blackheads using special tools like needles and forceps. Combination therapy is the latest trend in the acne drug market. Combination therapy is the process of combining two drugs with different mechanisms of action, such combinations of medication have better efficacy and adherence when compared with monotherapy (the use of only a single drug by itself). The combination of a topical retinoid drug, which unclogs the pores, along with an antimicrobial drug, which is used to treat an infection is being used to treat acne drugs. Example of combination therapy includes Epiduo, Acanya, Ziana, and Benzamycin produced by Galderma, Allergan, Medicis, and Atrix respectively. The stringent regulations concerning the usage of drugs to treat Acne Drugs have an impact on the acne drug market. The regulations have become more stringent due to the various side effects and adverse events caused during treatment. In India, the Central Drugs Standard Control Organization (CDSCO) has issued a warning regarding the safety guidelines concerning the use of the oral drug, isotretinoin. The CDSCO has directed the states and union territories’ drug controllers to check the labelling of isotretinoin drugs and make end users aware of the serious birth defects the drug may cause. Further, the Subject Expert Committee (SEC) for Dermatology and Allergy has recommended that the drug should be sold only under the prescription of a dermatologist, manufacturers should provide a package insert in local languages, and retail pharmacies should maintain the details of retail sale of the drug. Hence, these strict guidelines and regulations would impact the growth of the acne drug market. In December 2021, Sanofi S.A., a France based pharmaceutical and healthcare company specialising in drug development and commercialization, acquired Origimm Biotechnology GmbH for an undisclosed amount. Through this acquisition, Sanofi increases its vaccine R&D pipeline, skin microbiome and skin immunology expertise, and treatment options for acne disease. And the product will reach the rest of Europe. Origimm Biotechnology GmbH is an Austria based pharmaceutical company pioneering in the identification of pathogenic skin microbiome components and skin disease-causing bacterial antigens. North America was the largest region in the acne drugs market in 2022. The Middle East is expected to be the largest growing region in the global acne drugs market during the forecast period. The regions covered in the global acne drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the acne drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The acne drugs market consists of sales of retinoids, antibiotics, and diapsone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The acne drugs market research report is one of a series of new reports from The Business Research Company that provides acne drugs market statistics, including acne drugs industry global market size, regional shares, competitors with an acne drugs market share, detailed acne drugs market segments, market trends and opportunities, and any further data you may need to thrive in the acne drugs industry. This acne drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Skin cancer drugs refer to chemotherapy drugs that are used to treat skin cancer. Skin cancer refers to aberrant skin cell proliferation, which most frequently appears on sun-exposed skin. However, this prevalent type of cancer can also develop on parts of your skin that are not often exposed to sunlight. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma, or melanoma. Examples of skin cancer drugs include 5-FU, Aldara, and Efudex. The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Actinic keratoses are broad, rough skin patches that can turn cancerous. It commonly appears on sun-exposed regions such as the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents and other drugs and are used in various sectors such as hospitals, cancer research centers, and clinics. The global skin cancer drugs market is segmented - 1) By Type: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma 2) By End Users: Hospitals, Cancer Research Centers, Clinics 3) By Drug Class: Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs The global skin cancer drugs market size will grow from $3.03 billion in 2022 to $3.41 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global skin cancer drugs is expected to grow to $5.23 billion in 2027 at a CAGR of 11.3%. A significant rise in the prevalence of skin cancer is driving the demand for drugs for Skin Cancer. To treat such high cases of skin cancer, more new innovative skin cancer drugs are being manufactured.in 2022, according to The American Cancer Society, a US-based organization, approximately 99,780 new melanoma skin cancer is diagnosed and approximately 7,650 people are expected to die of melanoma skin cancer every year. This is boosting the demand for skin cancer drugs and thus driving the skin cancer drugs market. Major players in the skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd., Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC, and Pfizer Inc. The increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs target melanoma cells only. The chemical drugs attack any fast-dividing cells while targeted therapies only attack the skin cancer-causing melanoma cells. Thus, doctors prefer targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the skin cancer drugs market going forward. Companies in the Skin Cancer Market are increasingly looking for Strategic Alliances with other companies in the market. Strategic Alliance would help companies to enhance their R&D capability, expedite the development process of new drugs, and reinforce their competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies for the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug for skin cancer. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for the safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. EMA also regulates and supervises the drug quality, checking for the intended use of the drug and whether the drug is meeting the requirement of a clinical trial. EMA also educates the patients regarding the risks associated with taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, the benefits of the drug, and all other relevant information about such drugs. In April 2022, Regeneron, a US-based biotechnology company acquired Checkmate Pharmaceuticals for $250 million. Through this acquisition, Regeneron expands its research efforts in immuno-oncology potential approaches for difficult-to-treat cancers. Checkmate Pharmaceuticals is a US-based company operating in skin cancer drugs. North America was the largest region in the skin cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global skin cancer drugs market during the forecast period. The regions covered in the global skin cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The skin cancer drugs market consists of sales of vismodegib (Erivedge) and sonidegib (Odomzo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The skin cancer drugs market research report is one of a series of new reports from The Business Research Company that provides skin cancer drugs market statistics, including skin cancer drugs industry global market size, regional shares, competitors with a skin cancer drugs market share, detailed skin cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer drugs industry. This skin cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erectile dysfunction (ED) drugs refer to the drugs that are used to improve the effects of nitric oxide, a substance your body naturally generates that relaxes penile muscles, to treat erectile dysfunction. Erectile dysfunction is the inability to achieve or keep up a penile erection in men. The different types of drugs in erectile dysfunction (ED) drugs are sildenafil citrate, mirodenafil, and vardenafil. Sildenafil is a drug that is used to treat erectile dysfunction and pulmonary arterial hypertension. It is offered under the trade names Viagra and others. It’s unknown whether it’s effective in treating female genital dysfunction. The different routes of administration include Oral, topical, and injections and are used by hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for erectile dysfunction market is segmented - 1) By Drugs: Sildenafil Citrate, Mirodenafil, Vardenafil 2) By End users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Mode of Administration: Oral, Topical, Injections The global drugs for erectile dysfunction market size will grow from $3.21 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 1.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for erectile dysfunction market size is expected to grow to $3.36 billion in 2027 at a CAGR of 0.8%. The drastic increase in the number of chronic diseases drives the erectile dysfunction drug market. Erectile dysfunction is mainly caused by chronic diseases resulting from a sedentary lifestyle such as cardiovascular diseases, diabetes, obesity, and high blood pressure. According to WHO, the prevalence of chronic diseases is expected to grow by 57% by the end of the year 2020. Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drug market. Major players in the erectile dysfunction (ED) drugs market are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd., Vivus, Meda Pharmaceuticals, Apricus Biosciences, Cristália, S.K. Chemicals Co and Teva Pharmaceutical Industries Ltd. Patients suffering from erectile dysfunction do not seek treatment owing to factors such as lack of education, lack of awareness, strong religious beliefs, social taboo, and low socioeconomic status. These factors are responsible for the patients suffering from erectile dysfunction rejecting or avoiding the treatment. For example, according to a survey conducted by Opinium Research in February 2020, just 27% out of the total 2,006 men surveyed were aware that erectile dysfunction could be linked to high blood pressure or elevated cholesterol while just 22% of men surveyed were aware that erectile dysfunction is often associated with diabetes. These factors restrain the growth of the erectile dysfunction drug market. New drug delivery techniques such as the use of pellets and creams are being implemented by many companies in the erectile dysfunction drugs market. Pellets and creams will have more efficacy and performance in erectile dysfunction and these are also more effective and safer to use. These benefits from drug delivery techniques will increase the scope of the erectile dysfunction drug market. For example, In September 2022, Lupin, an India-based pharmaceutical company launched Sildenafil for oral suspension, 10 mg/mL with the approval of the United States Food and Drug Administration (FDA). This drug is for erectile dysfunction with unique dosages. Medicines are authorized by regulatory bodies based on quality, safety, and efficacy to make sure that medicines are of standard quality and gives positive benefit. Companies are mandated to submit the documentation for the standard quality before applying for authorization. The safety and efficacy of medicines should be demonstrated by clinical trials for all new medicines by the companies. Competent authorities will assess this data before authorizing the drugs. In Europe, the European Medicines Agency (EMA) assesses the drugs for centrally authorized products. North America was the largest region in the erectile dysfunction (ED) drugs market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the global erectile dysfunction (ED) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the erectile dysfunction (ED) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The erectile dysfunction (ED) drugs market consists of sales Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis) and avanafil (Stendra). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The erectile dysfunction (ED) drugs market research report is one of a series of new reports from The Business Research Company that provides erectile dysfunction (ED) drugs market statistics, including erectile dysfunction (ED) drugs industry global market size, regional shares, competitors with erectile dysfunction (ED) drugs market share, detailed erectile dysfunction (ED) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction (ED) drugs industry. This erectile dysfunction (ED) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibres in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50. The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others. Alpha-blockers, commonly known as "blockers" or "adrenoreceptor antagonists," are a type of pharmaceutical drug that works by blocking adrenergic receptors. The different sectors include hospital pharmacies, retail pharmacies, and others and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for benign prostatic hypertrophy market is segmented - 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types 2) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global drugs for benign prostatic hypertrophy market size will grow from $6.45 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for benign prostatic hypertrophy is expected to grow to $8.18 billion in 2027 at a CAGR of 4.5%. The rising male geriatric population globally is driving the growth of drugs for benign prostatic hypertrophy market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years. Major players in the drugs for benign prostatic hypertrophy market are Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation, and AEternaZentaris Inc. Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of the Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT), and transurethral needle ablation (TUNA). Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects, and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy. Benign prostatic hypertrophy drug manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate the safety and efficacy of drugs using clinical trial data, which will be assessed by competent authorities before authorizing for sale. North America was the largest region in the drugs for benign prostatic hypertrophy market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for benign prostatic hypertrophy market share. The regions covered in the global drugs for benign prostatic hypertrophy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.